How to identify and eliminate compounds with a risk of high clinical dose during the early phase of lead optimisation in drug discovery.

An alternative approach has been developed to estimate the clinical dose of new drug molecules at an early stage in the drug discovery process. This approach has been compared to traditional methods using the clinical dose as indicated on the drug label of 136 marketed drugs. At the early stages of drug discovery only in silico predictions or some initial… (More)